©2024 Stanford Medicine
Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases
Not Recruiting
Trial ID: NCT01778764
Purpose
The investigators will learn from this study if the CyberKnife radiosurgery (CK RS) treatment
of patients with 1-3 versus 4 or more brain metastases results in the same overall survivals.
The importance of this new knowledge will be to determine the treatment efficacy of CK RS
with 1-3 versus 4 or more brain metastases. The outcome of this trial would give data to
support either the continuation or modification of the CK RS treatment of patients with brain
metastases.
Official Title
A Comparison of Overall Survival Post-CyberKnife Radiosurgery Treatment of Patients With 1-3 Versus 4 or More Brain Metastases
Stanford Investigator(s)
Steven D. Chang, MD
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
Iris C. Gibbs, MD, FACR, FASTRO
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
1. the presence of a tumor metastasis or tumor metastases to the brain as manifested by
the neurological examination and visibility of the metastatic lesion(s) on MRI and CT
scans
2. a Karnofsky performance status (KPS) score of greater than or equal to 60.
Exclusion Criteria:
The exclusion criteria are the converse of the above, i.e. patients without a brain tumor
metastasis or brain tumor metastases or a KPS of less than 60.
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Steven Chang
650-723-5573